Vidofludimus

• CAT Number: I004676
• CAS Number: 717824-30-1
• Molecular Formula: C20H18FNO4
• Molecular Weight: 355.40
• Purity: ≥95%
• Target: Immunology/Inflammation
• Solubility: DMSO: ≥ 46 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
• InChIKey: XPRDUGXOWVXZLL-UHFFFAOYSA-N
• SMILES: COC1=CC(C2=CC(F)=C(NC(C3=C(C(O)=O)CCC3)=O)C=C2)=CC=C1

Vidofludimus (Cat No.: I004676) is an orally active, selective dihydroorotate dehydrogenase (DHODH) inhibitor with immunomodulatory and anti-inflammatory properties. By blocking DHODH, it suppresses de novo pyrimidine synthesis, leading to reduced proliferation of activated T and B lymphocytes. Vidofludimus has been investigated for treating autoimmune and inflammatory diseases, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. It also exhibits antiviral activity by impairing viral replication. Its dual mechanism of immune regulation and antiviral action makes Vidofludimus a promising candidate in clinical and pharmacological research.

Reference

1:Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF.J Crohns Colitis. 2013 Sep;7(8):636-43. doi: 10.1016/j.crohns.2012.09.016. Epub 2012 Oct 16. PMID: 23078909 2:Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. Fitzpatrick LR, Small JS, Doblhofer R, Ammendola A.J Pharmacol Exp Ther. 2012 Sep;342(3):850-60. doi: 10.1124/jpet.112.192203. Epub 2012 Jun 12. PMID: 22691298 Free Article3:New preclinical findings with vidofludimus. [No authors listed]Immunotherapy. 2010 Jul;2(4):439. No abstract available. PMID: 20648986